DOCSLIB.ORG

Application Number

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Application Number CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 207145Orig1s000 PHARMACOLOGY REVIEW(S) Tertiary Pharmacology Review By: Paul C. Brown, Ph.D., ODE Associate Director for Pharmacology and Toxicology, OND IO NDA: 207145 Submission date: 5/29/2014 Drug: Safinamide Applicant: Newron Pharmaceuticals Indication: adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes Reviewing Division: Division of Neurology Products Discussion: The primary reviewer and supervisor found the nonclinical information adequate to support the approval of safinamide for the indication listed above. Safinamide is an inhibitor of monoamine oxidase B. Although the exact mechanism by which safinamide exerts it therapeutic effect is not known, increased dopaminergic activity in the brain induced by inhibition of monoamine oxidase B is thought to be beneficial in Parkinson’s disease. The Established Pharmacologic Class of Monoamine Oxidase Type B Inhibitor is appropriate for safinamide. The carcinogenicity of safinamide was assessed in 2-year rat and mouse studies. These studies were found to be acceptable by the executive carcinogenicity assessment committee and the committee concluded that there were no drug- related neoplasms in either species. Retinal toxicity and cataracts were observed in rats treated with safinamide. These effects occurred at exposures below those achieved in humans at the maximum recommended dose. The relevance to humans is unknown but cannot be excluded. Proposed labeling includes warning about this possible toxicity. Safinamide alone and in combination with levodopa and carbidopa produced adverse developmental effects in animals at doses similar to those used in humans. Proposed labeling includes description of these findings. Conclusions: I agree that this NDA can be approved from a pharm/tox perspective for the indication listed above. 1 Reference ID: 3904554 --------------------------------------------------------------------------------------------------------- This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature. --------------------------------------------------------------------------------------------------------- /s/ ---------------------------------------------------- PAUL C BROWN 03/18/2016 Reference ID: 3904554 MEMORANDUM DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration ________________________________________________________________________ Division of Neurology Products (HFD-120) Center for Drug Evaluation and Research Date: March 14, 2016 From: Lois M. Freed, Ph.D. Supervisory Pharmacologist Subject: NDA 207-145 (safinamide, Xadago) ________________________________________________________________________ NDA 207-145 was submitted by Newron Pharmaceuticals on May 27, 2014 (received May 29, 2014) for safinamide as add-on therapy for treatment of idiopathic Parkinson's disease. On August 31, 2015, the sponsor submitted a major amendment, resulting in an extension of the user fee goal date. Clinical development was conducted under IND 63901; a pre-NDA meeting was held with the sponsor on September 16, 2013 (cf. PreNDA meeting minutes, October 16, 2013). The sponsor has conducted a comprehensive battery of nonclinical studies to support clinical development of safinamide and the NDA. In addition to the standard nonclinical studies to support a chronic indication (including chronic toxicity, reproductive and development toxicology, and carcinogenicity studies and genotoxicity assays), the sponsor conducted toxicology studies of safinamide in combination with levodopa/carbidopa and pramipexole and mechanistic studies to address the retinal and developmental toxicities observed in rodent. The nonclinical studies were reviewed by Drs. Terry Peters and LuAnn McKinney under IND 63901 and by Dr. LuAnn McKinney under the NDA (Pharmacology/Toxicology NDA Review and Evaluation, LuAnn McKinney, DVM, DACVP, December 4, 2015). Dr. McKinney’s review should be referenced for a detailed evaluation of the nonclinical data. Only selected findings are discussed below. Pharmacology According to the sponsor, safinamide (S-(+)-2-[4-(3-fluorobenzyl) oxybenzyl] aminopropanamide methanesulfonate) exerts pharmacological activity through a "multi- modal mechanism of action," including MAO-B inhibition, state-dependent blockade of voltage gated sodium channels, and "inhibition of excessive release of glutamate." 1 Reference ID: 3901831 In vitro, safinamide inhibited MAO-B in rat and human brain (IC50’s of 98 and 79 nM, respectively) and liver (IC50’s of 79 and 52 nM, respectively). (Safinamide also inhibited MAO-A in rat and human brain but at substantially higher IC50's of 584 and 80 µM, respectively). MAO-B inhibition was demonstrated to be reversible in rat brain mitochondria and platelet-rich human plasma, based on the results of X-ray analysis and recovery of MAO-B activity in rat brain mitochondria with repeated washing. Safinamide exhibited no in vitro binding to dopamine receptors and low affinity (IC50 > 10 µM) for the dopamine or serotonin transporter. In vivo, safinamide increased dopamine levels (27-48% at 24 hrs post dose) in the putamen of cynomolgus monkey following 13 weeks of dosing at 10 and 20 mg/kg PO and prolonged the duration of anti-PD effects of levodopa (by 36-42 min) at 3-30 mg/kg PO in MPTP-lesioned cynomolgus monkey. Safinamide had no effect on the magnitude of anti-PD effects of levodopa at doses of 3- 30 mg/kg PO or 0.2-20 mg/kg PO in separate studies in MPTP-lesioned cynomolgus monkey. The sponsor hypothesizes that safinamide has unique therapeutic (e.g., anti-dyskinetic) effects in PD patients (compared to approved MAO-B inhibitors for PD, i.e., rasagiline and selegiline), mediated primary through blockade of voltage-gated sodium channels (VGSC). Blockade of VGSC by safinamide was observed in vitro in cortical neurons from E17 Wistar rat fetuses (IC50 of 33-96 µM), in primary rat cortical neurons (IC50 of ∼7 µM for the inactivated state), and of recombinant human VGSC (IC50 of 1.69-4.85 µM for inactivated state). Safinamide (30 mg/kg IP) also reduced sodium channel activator (veratridine) - induced glutamate release in the dorsal hippocampus of rat, assessed in vivo using microdialysis; the sponsor estimated a corresponding plasma unbound concentration of ∼0.6 µM, which is similar to that in humans at the maximum recommended daily dose of 100 mg (i.e., 0.26-0.77 µM). Data from in vivo studies in MPTP-lesioned, Parkinsonian, dyskinetic cynomolgus or rhesus monkeys were inconsistent. Some studies reported a reduction in levodopa-induced dyskinesia, whereas others demonstrated no anti-dyskinetic effects of safinamide. The sponsor stated that design of the studies demonstrating no anti-dyskinetic effects of safinamide “did not match” that of the positive studies because of “methodological differences in the experimental set up”; however, what those differences were and how they might explain the inconsistent results were not clarified. Overall, the sponsor’s nonclinical data do not clearly support the involvement of non- dopaminergic mechanisms in its therapeutic effects and suggest that inhibition of MAO- B is likely the most relevant mechanism for safinamide as adjunctive therapy in patients with idiopathic Parkinson’s disease. PK/ADME PK studies were conducted in rat (Sprague-Dawley, Wistar) and cynomolgus monkey. PK parameters following acute IV and PO doses are summarized in the following table: 2 Reference ID: 3901831 SPECIES/ DOSE/ C # T AUC t Cl V F SEX max max (0-∞) 1/2 ss STRAIN ROUTE (µg/mL) (hr) (µg*hr/mL) (hr) (L/h/kg) (L/kg) (%) Rat/ 5 IV 1.76 0.03 1.79 1.7 0.02 4.8 -- M Sprague-Dawley 10 PO 1.65 0.72 3.28 1.3 -- -- 92 M 0.31 0.1 0.27 1.3 2.8 3.4 -- 0.76 IV Rat/ F 0.36 0.1 0.46 1.7 1.7 2.9 -- Wistar M 0.24 0.25 0.5 2 -- -- 43 3 PO F 0.29 0.25 1.29 2.1 -- -- 54 Monkey/ 5 IV 3.85 0.08 11.5 12.7 0.45 2.4 -- M cynomolgus 10 PO 2.87 1.67 18.6 10.9 -- -- 80 # C0 for IV dose Tissue distribution studies were conducted in CD-1 mouse, rat (Sprague-Dawley, Wistar, Lister Hooded), and cynomolgus monkey following acute IV (1 mg/kg) and acute and repeat oral (1-10 mg/kg) safinamide doses. Distribution of radioactivity into tissues was widespread, consistent with Vss values. Distribution and half-life of radioactivity were greater in pigmented tissues compared to non-pigmented tissues in rat, suggesting binding to melanin. Urine was the major route of elimination in all species. The in vivo metabolic profile of safinamide following oral administration was assessed in CD-1 mouse, rat (Sprague-Dawley, Wistar), and cynomolgus monkey (also dog and minipig). Safinamide accounted for 9 and 30% of total plasma radioactivity in monkey and human, respectively, and was characterized as a minor component in rat plasma. NW-1689 (formed by oxidative N-dealkylation) was a major metabolite in all species, accounting for 47, 55, 45, and 30% of total radioactivity in mouse, rat, monkey, and human, respectively. NW-1153 (formed by amide hydrolysis) was a minor component in all species tested. In humans, NW-1689 AG, an acyl glucuronide, accounted for 16-18% of parent and ∼5% of total radioactivity. Although not a major metabolite in humans, acyl glucuronides have the potential to induce toxicity; therefore, the safety of NW-1689 AG was addressed by the sponsor. NW-1689-AG: The sponsor conducted in vitro studies to assess the potential reactivity
Load more

Recommended publications
  • Therapeutic Potential of Nicotinamide Adenine Dinucleotide (NAD) T ∗ Marta Arenas-Jala,B, , J.M
    European Journal of Pharmacology 879 (2020) 173158 Contents lists available at ScienceDirect European Journal of Pharmacology journal homepage: www.elsevier.com/locate/ejphar Therapeutic potential of nicotinamide adenine dinucleotide (NAD) T ∗ Marta Arenas-Jala,b, , J.M. Suñé-Negrea, Encarna García-Montoyaa a Pharmacy and Pharmaceutical Technology Department (Faculty of Pharmacy and Food Sciences), University of Barcelona, Barcelona, Spain b ICN2 – Catalan Institute of Nanoscience and Nanotechnology (Autonomous University of Barcelona), Bellaterra (Barcelona), Spain ARTICLE INFO ABSTRACT Keywords: Nicotinamide adenine nucleotide (NAD) is a small ubiquitous hydrophilic cofactor that participates in several NAD aspects of cellular metabolism. As a coenzyme it has an essential role in the regulation of energetic metabolism, Metabolism but it is also a cosubstrate for enzymes that regulate fundamental biological processes such as transcriptional Therapeutic potential regulation, signaling and DNA repairing among others. The fluctuation and oxidative state of NAD levels reg- Drug discovery ulate the activity of these enzymes, which is translated into marked effects on cellular function. While alterations Supplementation in NAD homeostasis are a common feature of different conditions and age-associated diseases, in general, in- creased NAD levels have been associated with beneficial health effects. Due to its therapeutic potential, the interest in this molecule has been renewed, and the regulation of NAD metabolism has become an attractive target for drug discovery. In fact, different approaches to replenish or increase NAD levels have been tested, including enhancement of biosynthesis and inhibition of NAD breakdown. Despite further research is needed, this review provides an overview and update on NAD metabolism, including the therapeutic potential of its regulation, as well as pharmacokinetics, safety, precautions and formulation challenges of NAD supplementa- tion.
    [Show full text]
  • Metabolic-Hydroxy and Carboxy Functionalization of Alkyl Moieties in Drug Molecules: Prediction of Structure Influence and Pharmacologic Activity
    molecules Review Metabolic-Hydroxy and Carboxy Functionalization of Alkyl Moieties in Drug Molecules: Prediction of Structure Influence and Pharmacologic Activity Babiker M. El-Haj 1,* and Samrein B.M. Ahmed 2 1 Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, University of Science and Technology of Fujairah, Fufairah 00971, UAE 2 College of Medicine, Sharjah Institute for Medical Research, University of Sharjah, Sharjah 00971, UAE; [email protected] * Correspondence: [email protected] Received: 6 February 2020; Accepted: 7 April 2020; Published: 22 April 2020 Abstract: Alkyl moieties—open chain or cyclic, linear, or branched—are common in drug molecules. The hydrophobicity of alkyl moieties in drug molecules is modified by metabolic hydroxy functionalization via free-radical intermediates to give primary, secondary, or tertiary alcohols depending on the class of the substrate carbon. The hydroxymethyl groups resulting from the functionalization of methyl groups are mostly oxidized further to carboxyl groups to give carboxy metabolites. As observed from the surveyed cases in this review, hydroxy functionalization leads to loss, attenuation, or retention of pharmacologic activity with respect to the parent drug. On the other hand, carboxy functionalization leads to a loss of activity with the exception of only a few cases in which activity is retained. The exceptions are those groups in which the carboxy functionalization occurs at a position distant from a well-defined primary pharmacophore. Some hydroxy metabolites, which are equiactive with their parent drugs, have been developed into ester prodrugs while carboxy metabolites, which are equiactive to their parent drugs, have been developed into drugs as per se.
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Questions in the Chemical Enzymology of MAO
    Review Questions in the Chemical Enzymology of MAO Rona R. Ramsay 1,* and Alen Albreht 2 1 Biomedical Sciences Research Complex, School of Biology, University of St Andrews, St Andrews KY16 9ST, UK 2 Laboratory for Food Chemistry, Department of Analytical Chemistry, National Institute of Chemistry, Hajdrihova 19, SI-1000 Ljubljana, Slovenia; [email protected] * Correspondence: [email protected]; Tel.: +44-(0)-1334-474740 Abstract: We have structure, a wealth of kinetic data, thousands of chemical ligands and clinical information for the effects of a range of drugs on monoamine oxidase activity in vivo. We have comparative information from various species and mutations on kinetics and effects of inhibition. Nevertheless, there are what seem like simple questions still to be answered. This article presents a brief summary of existing experimental evidence the background and poses questions that remain intriguing for chemists and biochemists researching the chemical enzymology of and drug design for monoamine oxidases (FAD-containing EC 4.1.3.4). Keywords: chemical mechanism; kinetic mechanism; oxidation; protein flexibility; cysteine modifica- tion; reversible/irreversible inhibition; molecular dynamics; simulation 1. Introduction Monoamine oxidase (E.C. 1.4.3.4) enzymes MAO A and MAO B are FAD-containing Citation: Ramsay, R.R.; Albreht, A. proteins located on the outer face of the mitochondrial inner membrane, retained there Questions in the Chemical Enzymology of MAO. Chemistry 2021, by hydrophobic interactions and a transmembrane helix. The redox co-factor (FAD) is 3, 959–978. https://doi.org/10.3390/ covalently attached to a cysteine and buried deep inside the protein [1].
    [Show full text]
  • Azilect, INN-Rasagiline
    SCIENTIFIC DISCUSSION 1. Introduction AZILECT is indicated for the treatment of idiopathic Parkinson’s disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations. Rasagiline is administered orally, at a dose of 1 mg once daily with or without levodopa. Parkinson’s disease is a common neurodegenerative disorder typified by loss of dopaminergic neurones from the basal ganglia, and by a characteristic clinical syndrome with cardinal physical signs of resting tremor, bradikinesia and rigidity. The main treatment aims at alleviating symptoms through a balance of anti-cholinergic and dopaminergic drugs. Parkinson’s disease (PD) treatment is complex due to the progressive nature of the disease, and the array of motor and non-motor features combined with early and late side effects associated with therapeutic interventions. Rasagiline is a chemical inhibitor of the enzyme monoamine oxidase (MAO) type B which has a major role in the inactivation of biogenic and diet-derived amines in the central nervous system. MAO has two isozymes (types A and B) and type B is responsible for metabolising dopamine in the central nervous system; as dopamine deficiency is the main contributing factor to the clinical manifestations of Parkinson’s disease, inhibition of MAO-B should tend to restore dopamine levels towards normal values and this improve the condition. Rasagiline was developed for the symptomatic treatment of Parkinson’s disease both as monotherapy in early disease and as adjunct therapy to levodopa + aminoacids decarboxylase inhibitor (LD + ADI) in patients with motor fluctuations. 2. Quality Introduction Drug Substance • Composition AZILECT contains rasagiline mesylate as the active substance.
    [Show full text]
  • Evidence That Formulations of the Selective MAO-B Inhibitor, Selegiline, Which Bypass First-Pass Metabolism, Also Inhibit MAO-A in the Human Brain
    Neuropsychopharmacology (2015) 40, 650–657 OPEN & 2015 American College of Neuropsychopharmacology. All rights reserved 0893-133X/15 www.neuropsychopharmacology.org Evidence that Formulations of the Selective MAO-B Inhibitor, Selegiline, which Bypass First-Pass Metabolism, also Inhibit MAO-A in the Human Brain Joanna S Fowler*,1, Jean Logan2, Nora D Volkow3,4, Elena Shumay4, Fred McCall-Perez5, Millard Jayne4, Gene-Jack Wang4, David L Alexoff1, Karen Apelskog-Torres4, Barbara Hubbard1, Pauline Carter1, 1 6 7 4 1 1 4 Payton King , Stanley Fahn , Michelle Gilmor , Frank Telang , Colleen Shea , Youwen Xu and Lisa Muench 1Biological, Environmental and Climate Sciences Department, Brookhaven National Laboratory, Upton, NY, USA; 2New York University Langone Medical Center, Department of Radiology, New York, NY, USA; 3National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, 4 5 USA; National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA; Targeted Medical Pharma Inc, 6 7 Los Angeles, CA, USA; Department of Neurology, Columbia University Medical Center, New York, NY, USA; Novartis Pharmaceuticals, East Hanover, NJ, USA Selegiline (L-deprenyl) is a selective, irreversible inhibitor of monoamine oxidase B (MAO-B) at the conventional dose (10 mg/day oral) that is used in the treatment of Parkinson’s disease. However, controlled studies have demonstrated antidepressant activity for high doses of oral selegiline and for transdermal selegiline suggesting that when plasma levels of selegiline are elevated, brain MAO-A might also be inhibited. Zydis selegiline (Zelapar) is an orally disintegrating formulation of selegiline, which is absorbed through the buccal mucosa producing higher plasma levels of selegiline and reduced amphetamine metabolites compared with equal doses of conventional selegiline.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Drugbank 3.0: a Comprehensive Resource for 'Omics' Research On
    Published online 8 November 2010 Nucleic Acids Research, 2011, Vol. 39, Database issue D1035–D1041 doi:10.1093/nar/gkq1126 DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs Craig Knox1, Vivian Law2, Timothy Jewison1, Philip Liu3, Son Ly2, Alex Frolkis1, Allison Pon1, Kelly Banco2, Christine Mak2, Vanessa Neveu1, Yannick Djoumbou3, Roman Eisner1, An Chi Guo1 and David S. Wishart1,2,3,4,* 1Department of Computing Science, University of Alberta, Edmonton, AB, Canada T6G 2E8, 2Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada T6G 2N8, 3Department of Biological Sciences, University of Alberta, Edmonton, AB, Canada T6G 2E8 and 4National Institute for Nanotechnology, 11421 Saskatchewan Drive, Edmonton, AB, Canada T6G 2M9 Received September 15, 2010; Revised October 20, 2010; Accepted October 21, 2010 ABSTRACT drug target, drug description and drug action data. DrugBank (http://www.drugbank.ca) is a richly DrugBank 3.0 represents the result of 2 years annotated database of drug and drug target infor- of manual annotation work aimed at making mation. It contains extensive data on the nomencla- the database much more useful for a wide ture, ontology, chemistry, structure, function, range of ‘omics’ (i.e. pharmacogenomic, action, pharmacology, pharmacokinetics, metabol- pharmacoproteomic, pharmacometabolomic and ism and pharmaceutical properties of both small even pharmacoeconomic) applications. molecule and large molecule (biotech) drugs. It also contains comprehensive information on the INTRODUCTION target diseases, proteins, genes and organisms on which these drugs act. First released in 2006, Historically most of the known information on drugs, DrugBank has become widely used by pharmacists, drug targets and drug action has resided in books, medicinal chemists, pharmaceutical researchers, journals and expensive commercial databases.
    [Show full text]
  • Smart Drugs: a Review
    International Journal for Innovation Education and Research www.ijier.net Vol:-8 No-11, 2020 Smart Drugs: A Review Sahjesh Soni, Dr Rashmi Srivastava, Ayush Bhandari Mumbai Educational Trust, India Abstracts Smart drugs can change the way our mind functions. Smart drugs are also known as nootropics, which literally means the ability to bend or shape our mind. Smart drugs are classified into two main categories. They are classified based on their pharmacological action and their availability. The stimulant category of drugs is highly used and misused. There has been a rampant increase in the sale of smart drugs, which could be attributed to the rise in competition all over the world. Two major criteria for selecting a good drug are its mechanism of action and bioavailability. Owing to the short-term benefits of smart drugs, many countries have openly accepted this concept. There is still no concrete scientific evidence backing the safety and efficacy of these drugs. Some believe that this is just a fad that will soon pass, while others believe that this is something that will revolutionize our future. Key Words: Smart drugs, Nootropics, Cognitive enhancers, Stimulants, Uses and Side effects. What are Smart Drugs? "Smart drugs" are a group of compounds that can promote brain performance. They have got a lot of attention due to our stressful lifestyle, and these drugs help to boost our memory, focus, creativity, intelligence, and motivation. The origin of the word comes from the Greek language meaning “to bend or shape the mind”.1 These chemicals have many mechanisms of action.
    [Show full text]
  • Drug Knowledge Bases and Their Applications in Biomedical Informatics Research Yongjun Zhu, Olivier Elemento, Jyotishman Pathak and Fei Wang
    Briefings in Bioinformatics, 2018, 1–14 doi: 10.1093/bib/bbx169 Paper Drug knowledge bases and their applications in biomedical informatics research Yongjun Zhu, Olivier Elemento, Jyotishman Pathak and Fei Wang Corresponding author: Fei Wang, Division of Health Informatics, Department of Healthcare Policy and Research at Weill Cornell Medicine at Cornell University, 425 East 61st Street, Suite 301, DV-308, New York, NY 10065, USA. E-mail: [email protected] Abstract Recent advances in biomedical research have generated a large volume of drug-related data. To effectively handle this flood of data, many initiatives have been taken to help researchers make good use of them. As the results of these initiatives, many drug knowledge bases have been constructed. They range from simple ones with specific focuses to comprehensive ones that contain information on almost every aspect of a drug. These curated drug knowledge bases have made significant contributions to the development of efficient and effective health information technologies for better health-care service delivery. Understanding and comparing existing drug knowledge bases and how they are applied in various biomedical studies will help us recognize the state of the art and design better knowledge bases in the future. In addition, researchers can get insights on novel applications of the drug knowledge bases through a review of successful use cases. In this study, we provide a review of existing popular drug knowledge bases and their applications in drug-related studies. We discuss challenges in constructing and using drug knowledge bases as well as future research directions toward a better ecosystem of drug knowledge bases.
    [Show full text]
  • Computational Drug Repurposing Algorithm Targeting TRPA1 Calcium Channel As a Potential Therapeutic Solution for Multiple Sclerosis
    Supplementary Materials: Computational Drug Repurposing Algorithm Targeting TRPA1 Calcium Channel as a Potential Therapeutic Solution for Multiple Sclerosis Dragos Paul Mihai, George Mihai Nitulescu *, George Nicolae Daniel Ion, Cosmin Ionut Ciotu, Cornel Chirita, and Simona Negres Table S1. Descriptive statistics for pIC50 and druglikeness-related descriptors for the TRPA1 inhibitors set. Descriptor Range Minimum Maximum Mean ± SD pIC50 (M) 4.48 4.52 9.00 6.57 ± 1.01 ALogP 8.28 −0.71 7.57 4.02 ± 1.34 Molecular weight 482.03 175.10 657.13 389.70 ± 101.73 Polar surface area 193.59 17.82 211.41 82.80 ± 40.83 Rotatable bonds 12 1 13 5.01 ± 2.08 Hydrogen bonds acceptors 8 0 8 2.92 ± 1.46 Hydrogen bonds donors 3 0 3 1.06 ± 0.54 SD – standard deviation. Figure S1. Diagram of similarity/activity cliffs based on flexophores with 80% similarity within TRPA1 inhibitors. Larger dots indicate the presence of an activity cliff. Figure S2. Representative structures for similarity/activity cliffs analysis of TRPA1 inhibitors. Table S2. Highest similarity pairs between TRPA1 inhibitors and screened drugs based on flexophore descriptors data mining procedure. TRPA1 inhibitors Repurposing dataset Entry Similarity (ChEMBL ID) (DrugBank ID) 1 CHEMBL3298238 DB08135 0.9832 2 CHEMBL3220230 DB08561 0.9696 3 CHEMBL3220228 DB08561 0.9614 4 CHEMBL593902 DB07311 0.9553 5 CHEMBL3297780 DB01065 0.9533 6 CHEMBL3220448 DB08561 0.9509 Figure S3. Diagram of similarity/activity cliffs based on flexophores with 80% similarity threshold for merged TRPA1 inhibitors dataset (colored dots) and similar DrugBank entries (grey dots). Table S3.
    [Show full text]
  • Package 'Dbparser'
    Package ‘dbparser’ August 26, 2020 Title 'DrugBank' Database XML Parser Version 1.2.0 Description This tool is for parsing the 'DrugBank' XML database <https://www.drugbank.ca/>. The parsed data are then returned in a proper 'R' dataframe with the ability to save them in a given database. License MIT + file LICENSE Encoding UTF-8 LazyData true Imports DBI, dplyr, odbc, progress, purrr, readr, RMariaDB, RSQLite, tibble, tools, XML RoxygenNote 7.1.0 Suggests knitr, rmarkdown, testthat VignetteBuilder knitr URL https://docs.ropensci.org/dbparser/, https://github.com/ropensci/dbparser/ BugReports https://github.com/ropensci/dbparser/issues Depends R (>= 2.10) NeedsCompilation no Author Mohammed Ali [aut, cre], Ali Ezzat [aut], Hao Zhu [rev], Emma Mendelsohn [rev] Maintainer Mohammed Ali <[email protected]> Repository CRAN Date/Publication 2020-08-26 12:10:03 UTC 1 2 R topics documented: R topics documented: articles . .3 attachments . .5 books . .8 cett.............................................. 10 cett_actions_doc . 12 cett_doc . 14 cett_ex_identity_doc . 17 cett_go_doc . 19 cett_poly_doc . 21 cett_poly_pfms_doc . 24 cett_poly_syn_doc . 26 dbparser . 28 drugs . 29 drug_affected_organisms . 31 drug_ahfs_codes . 33 drug_atc_codes . 35 drug_calc_prop . 36 drug_categories . 38 drug_classification . 40 drug_dosages . 42 drug_element . 44 drug_element_options . 46 drug_exp_prop . 47 drug_external_links . 49 drug_ex_identity . 51 drug_food_interactions . 53 drug_general_information . 54 drug_groups . 57 drug_interactions . 58 drug_intern_brand
    [Show full text]